Karyopharm Faces Nasdaq Delisting Following Chapter 11 Filing

Bitget2026/11/05 12:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nasdaq notified Karyopharm Therapeutics on November 4, 2026, that its securities will be delisted following its Chapter 11 bankruptcy filing.
The company and subsidiary KPT Texas filed bankruptcy petitions on November 2, 2026, in the Southern District of Texas.
Nasdaq cited public interest concerns, existing shareholders' residual equity interests and continued-listing compliance risks. The company will not appeal.
Trading in the company's common stock will be suspended on Nasdaq at the opening of business on November 11, 2026.
The common stock is expected to begin over-the-counter trading on or after November 11, 2026, under KPTIQ, replacing KPTI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-448516), on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Karyopharm Faces Nasdaq Delisting Following Chapter 11 Filing

You may also like

Crypto prices